{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:22:14Z","timestamp":1777083734741,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00259-019-04438-w","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T02:02:14Z","timestamp":1564192934000},"page":"2289-2297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparison of PSMA-ligand PET\/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4492-4243","authenticated-orcid":false,"given":"Ali","family":"Afshar-Oromieh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Vollnberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandrine","family":"B\u00e4hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Sachpekidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotte","family":"Dijkstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvan","family":"Boxler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Holland-Letz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Thalmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Heverhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi","family":"H\u00e4rm\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin H.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,27]]},"reference":[{"key":"4438_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424. \n                    https:\/\/doi.org\/10.3322\/caac.21492\n                    \n                  .","journal-title":"CA Cancer J Clin"},{"key":"4438_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.eururo.2016.05.043","volume":"70","author":"MC Wong","year":"2016","unstructured":"Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70:862\u201374. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.05.043\n                    \n                  .","journal-title":"Eur Urol"},{"key":"4438_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0094-0143(02)00182-9","volume":"30","author":"B Kessler","year":"2003","unstructured":"Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin N Am. 2003;30:219\u201326.","journal-title":"Urol Clin N Am"},{"key":"4438_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618\u201329. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.08.003\n                    \n                  .","journal-title":"Eur Urol"},{"key":"4438_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197\u2013209. \n                    https:\/\/doi.org\/10.1007\/s00259-014-2949-6\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4438_CR6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","volume":"39","author":"A Afshar-Oromieh","year":"2012","unstructured":"Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085\u20136. \n                    https:\/\/doi.org\/10.1007\/s00259-012-2069-0\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4438_CR7","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","volume":"44","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258\u201368. \n                    https:\/\/doi.org\/10.1007\/s00259-017-3711-7\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4438_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486\u201395. \n                    https:\/\/doi.org\/10.1007\/s00259-012-2298-2\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4438_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11\u201320. \n                    https:\/\/doi.org\/10.1007\/s00259-013-2525-5\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4438_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668\u201374. \n                    https:\/\/doi.org\/10.2967\/jnumed.115.154153\n                    \n                  .","journal-title":"J Nucl Med"},{"key":"4438_CR11","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.eururo.2018.01.006","volume":"73","author":"I Rauscher","year":"2018","unstructured":"Rauscher I, Duwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, et al. Efficacy, predictive factors, and prediction nomograms for (68)Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography\/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy. Eur Urol. 2018;73:656\u201361. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2018.01.006\n                    \n                  .","journal-title":"Eur Urol"},{"key":"4438_CR12","doi-asserted-by":"publisher","first-page":"79S","DOI":"10.2967\/jnumed.115.170720","volume":"57","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, et al. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57:79S\u201389S. \n                    https:\/\/doi.org\/10.2967\/jnumed.115.170720\n                    \n                  .","journal-title":"J Nucl Med"},{"key":"4438_CR13","doi-asserted-by":"publisher","first-page":"153601211877606","DOI":"10.1177\/1536012118776068","volume":"17","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA theranostics: current status and future directions. Mol Imaging. 2018;17:1536012118776068. \n                    https:\/\/doi.org\/10.1177\/1536012118776068\n                    \n                  .","journal-title":"Mol Imaging"},{"key":"4438_CR14","doi-asserted-by":"publisher","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","volume":"58","author":"M Eiber","year":"2017","unstructured":"Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58:67S\u201376S. \n                    https:\/\/doi.org\/10.2967\/jnumed.116.186767\n                    \n                  .","journal-title":"J Nucl Med"},{"key":"4438_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00259-015-3251-y","volume":"43","author":"CO Sahlmann","year":"2016","unstructured":"Sahlmann CO, Meller B, Bouter C, Ritter CO, Strobel P, Lotz J, et al. Biphasic (6)(8)Ga-PSMA-HBED-CC-PET\/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:898\u2013905. \n                    https:\/\/doi.org\/10.1007\/s00259-015-3251-y\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4438_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.eururo.2015.12.051","volume":"70","author":"A Herlemann","year":"2016","unstructured":"Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, et al. (68)Ga-PSMA positron emission tomography\/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. 2016;70:553\u20137. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2015.12.051\n                    \n                  .","journal-title":"Eur Urol"},{"key":"4438_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.eururo.2015.04.034","volume":"68","author":"T Maurer","year":"2015","unstructured":"Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68:530\u20134. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2015.04.034\n                    \n                  .","journal-title":"Eur Urol"},{"key":"4438_CR18","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1007\/s00259-016-3366-9","volume":"43","author":"D Pfister","year":"2016","unstructured":"Pfister D, Porres D, Heidenreich A, Heidegger I, Knuechel R, Steib F, et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET\/CT. Eur J Nucl Med Mol Imaging. 2016;43:1410\u20137. \n                    https:\/\/doi.org\/10.1007\/s00259-016-3366-9\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4438_CR19","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/pros.23091","volume":"75","author":"S Hijazi","year":"2015","unstructured":"Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography\/computerized tomography. Prostate. 2015;75:1934\u201340. \n                    https:\/\/doi.org\/10.1002\/pros.23091\n                    \n                  .","journal-title":"Prostate"},{"key":"4438_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/ph7070779","volume":"7","author":"M Eder","year":"2014","unstructured":"Eder M, Neels O, Muller M, Bauder-Wust U, Remde Y, Schafer M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new pet tracer for imaging of prostate cancer. Pharmaceuticals. 2014;7:779\u201396. \n                    https:\/\/doi.org\/10.3390\/ph7070779\n                    \n                  .","journal-title":"Pharmaceuticals."},{"key":"4438_CR21","doi-asserted-by":"publisher","unstructured":"Bashir U, Tree A, Mayer E, Levine D, Parker C, Dearnaley D, et al. Impact of Ga-68-PSMA PET\/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2019;46(4):901\u20137. \n                    https:\/\/doi.org\/10.1007\/s00259-018-4249-z\n                    \n                  .","DOI":"10.1007\/s00259-018-4249-z"},{"key":"4438_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET\/CT and PET\/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887\u201397. \n                    https:\/\/doi.org\/10.1007\/s00259-013-2660-z\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4438_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ucl.2018.03.003","volume":"45","author":"MH Maurer","year":"2018","unstructured":"Maurer MH, Harma KH, Thoeny H. Diffusion-weighted genitourinary imaging. Urol Clin North Am. 2018;45:407\u201325. \n                    https:\/\/doi.org\/10.1016\/j.ucl.2018.03.003\n                    \n                  .","journal-title":"Urol Clin North Am"},{"key":"4438_CR24","doi-asserted-by":"publisher","unstructured":"Sawicki LM, Kirchner J, Buddensieck C, Antke C, Ullrich T, Schimmoller L, et al. Prospective comparison of whole-body MRI and (68)Ga-PSMA PET\/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2019;46(7):1542\u201350. \n                    https:\/\/doi.org\/10.1007\/s00259-019-04308-5\n                    \n                  .","DOI":"10.1007\/s00259-019-04308-5"},{"key":"4438_CR25","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1007\/s00259-018-4058-4","volume":"45","author":"HD Zacho","year":"2018","unstructured":"Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K, et al. Prospective comparison of (68)Ga-PSMA PET\/CT, (18)F-sodium fluoride PET\/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:1884\u201397. \n                    https:\/\/doi.org\/10.1007\/s00259-018-4058-4\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4438_CR26","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2967\/jnumed.116.173492","volume":"57","author":"I Rauscher","year":"2016","unstructured":"Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016;57:1713\u20139. \n                    https:\/\/doi.org\/10.2967\/jnumed.116.173492\n                    \n                  .","journal-title":"J Nucl Med"},{"key":"4438_CR27","doi-asserted-by":"publisher","unstructured":"Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, et al. A prospective, multi-site, international comparison of F-18 fluoro-methyl-choline, multi-parametric magnetic resonance and Ga-68 HBED-CC (PSMA-11) in men with high-risk features and biochemical failure after radical prostatectomy: clinical performance and patient outcomes. J Nucl Med. 2018;60(6):794\u2013800. \n                    https:\/\/doi.org\/10.2967\/jnumed.118.220103\n                    \n                  .","DOI":"10.2967\/jnumed.118.220103"},{"key":"4438_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.semradonc.2016.08.008","volume":"27","author":"D Moghanaki","year":"2017","unstructured":"Moghanaki D, Turkbey B, Vapiwala N, Ehdaie B, Frank SJ, McLaughlin PW, et al. Advances in prostate cancer magnetic resonance imaging and positron emission tomography-computed tomography for staging and radiotherapy treatment planning. Semin Radiat Oncol. 2017;27:21\u201333. \n                    https:\/\/doi.org\/10.1016\/j.semradonc.2016.08.008\n                    \n                  .","journal-title":"Semin Radiat Oncol"},{"key":"4438_CR29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2214\/AJR.18.19957","volume":"211","author":"TA Hope","year":"2018","unstructured":"Hope TA, Afshar-Oromieh A, Eiber M, Emmett L, Fendler WP, Lawhn-Heath C, et al. Imaging prostate cancer with prostate-specific membrane antigen PET\/CT and PET\/MRI: current and future applications. AJR Am J Roentgenol. 2018;211:286\u201394. \n                    https:\/\/doi.org\/10.2214\/AJR.18.19957\n                    \n                  .","journal-title":"AJR Am J Roentgenol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04438-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04438-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04438-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T23:09:45Z","timestamp":1595718585000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04438-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,27]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4438"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04438-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,27]]},"assertion":[{"value":"15 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This evaluation was approved by the ethics committee of the University of Bern (KEK-Nr. 2018\u201300299). All patients published in this manuscript signed a written informed consent form for the purpose of anonymized evaluation and publication of their data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}